| Document |
Document Title |
|
WO/2022/196178A1 |
To realize a method for producing glycolide that improves productivity of glycolide and suppresses generation of by-products. A method for producing glycolide that includes a first step for preparing a depolymerization reaction solution ...
|
|
WO/2022/183111A1 |
Described herein are compositions and methods for treating P. falciparum malaria by specifically activating apoptosis in cells that express PfGARP without activating apoptosis in subject host cells or parasite cells that do not express P...
|
|
WO/2022/177500A1 |
This invention relates to a method for the continuous production of optically pure lactide comprising the first reactive distillation, the second reactive distillation, the main distillation and the side-draw refluxer. For each of the fo...
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/163684A1 |
The present invention provides a modifier for resins such as polyester resins, polyester carbonate resins, and polycarbonate resins. The present invention further provides a cyclic diol compound useful as a resin modifier and a method fo...
|
|
WO/2022/158442A1 |
The present invention provides, as a radioactive halogen-labeled precursor compound that is highly stable and reactive, a compound represented by general formula (II) [in the formula, R1 and R2 each independently represent an alkyl group...
|
|
WO/2022/158993A1 |
The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2): Formula (2), or a salt thereof, wherein R1 is hydroge...
|
|
WO/2022/155762A1 |
Disclosed are a preparation method for preparing lactide and a reaction device. The preparation method comprises the following steps: (1) performing the following reaction in a reactive distillation column I: subjecting lactic acid to a ...
|
|
WO/2022/139675A1 |
This invention relates to a process for the continuous production of optically pure lactide from an aqueous solution of lactic acid by means of two reactive distillations followed by a main distillation column with a side-draw refluxer. ...
|
|
WO/2022/127163A1 |
Disclosed in the present invention are a stannous salt complex catalyst and a method for producing L-lactide by using same. The catalyst is obtained by reacting stannous salt and phosphite in a solvent. The oxidation of divalent stannous...
|
|
WO/2022/123319A1 |
The present disclosure provides pharmaceutical compositions and compounds having dual agonist activity at the μ and δ opioid receptors. The agonist compounds of this disclosure can also provide GPCR functional selectivity, including se...
|
|
WO/2022/089413A1 |
The present invention provides a method for refining glycolide and glycolide obtained using same. The method comprises the steps of using a solvent A to extract impurities from crude glycolide and then using a solvent B to perform recrys...
|
|
WO/2022/076041A1 |
Tagging agents, including fluorescent monomers, which may lack polymerizable double bonds. Anti-scalant polymer compositions that include a copolymer of a tagging agent and an anti-scalant monomer. Methods for synthesizing tagging agents...
|
|
WO/2022/061091A1 |
The present invention provides an amorphous form of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-ph
enylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoqui
nolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl
)p...
|
|
WO/2022/052223A1 |
An intensified microinterface preparation system and method for polyglycolic acid. The intensified microinterface preparation system comprises: a hydrogenation reactor, a hydrogen feed pipe, a hydrolysis reactor, and a water vapor feed p...
|
|
WO/2022/049219A1 |
The present invention is directed to pharmaceutical compounds of formula (I), formula (l-A) and formula (l-B) and compositions thereof that can prevent or treat viral infection.
|
|
WO/2022/043089A1 |
The invention relates to: a distillative method for preparing a diastereomer-enriched fragrance mixture; the diastereomer-enriched fragrance mixture; and the use thereof as a fragrance or for preparing a fragrance composition. The invent...
|
|
WO/2022/042829A1 |
The invention relates to a distillative process for producing a diastereomer-enriched scent mixture and to the diastereomer-enriched scent mixture and to the use thereof as a scent or for production of a scent preparation. The invention ...
|
|
WO/2022/045959A1 |
This invention relates to a process by means of distillation for the purification of lactide from a crude lactide vapor product stream, which crude lactide is produced by depolymerization of low molecular weight polylactic acid and is co...
|
|
WO/2022/033303A1 |
The present invention relates to a benzylamine derivative, a preparation method therefor and use thereof, and in particular, to a benzylamine derivative as represented by general formula (I), or a pharmaceutically acceptable stereoisomer...
|
|
WO/2022/035799A1 |
The disclosure is directed to, in part, to heterocycle CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
|
|
WO/2021/242806A1 |
The present invention relates to a methods and key intermediates useful for preparing the GLP‑1 receptor agonist (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-ph
enylpropyl)- 2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoqui...
|
|
WO/2021/225147A1 |
For the purpose of producing astatine-211 free from chloride ions with high yield, an astatine-211 production method is provided, the method being characterized by comprising: (1) a step for irradiating bismuth with an α ray to produce ...
|
|
WO/2021/225564A1 |
A method for producing lactide from С3-polyols, according to which, in a first step of the production process, catalytic conversion of alcohol mixtures of С3-polyols into methyl lactate is carried out on a solid catalyst in a flow-thro...
|
|
WO/2021/201449A1 |
The present invention relates to a compound for an organic electronic element, an organic electronic element using same, and an electronic device comprising the organic electronic element. According to the present invention, an organic e...
|
|
WO/2021/202986A1 |
The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors,...
|
|
WO/2021/192439A1 |
The purpose of the present invention is to provide: a compound which enables a liquid crystal composition to achieve a high voltage holding ratio (VHR); a liquid crystal composition which contains this compound; and a liquid crystal disp...
|
|
WO/2021/184014A1 |
Modular Meldrum's acid amine-reactive Michael acceptor (MaMa)- based molecules that are stable probes for high pH environments and bioconjugations. The molecules of the present invention can selectively label and protect lysine residues....
|
|
WO/2021/182457A1 |
[Problem] To develop novel compounds having an activity of inhibiting the function of Pin1 so as to use these compounds as pharmaceutical candidate compounds. [Solution] A compound represented by formula (I) or a salt thereof, and a Pin1...
|
|
WO/2021/178405A1 |
The first selective SuFEx antagonists to μ-opioid receptors (MOR) were developed by functionalizing an opioid scaffold with an SO2-F warhead. Our model, based on a MOR structure with antagonist β-FNA, indicates the naloxone carbonyl as...
|
|
WO/2021/162384A1 |
The present invention provides a novel compound capable of improving the luminous efficiency, stability, and lifespan of a device, an organic electric device using same, and an electronic device thereof.
|
|
WO/2021/153782A1 |
Provided is a method for controlling Phakopsora pachyrhizi which has an amino acid substitution F129L in the mitochondrial cytochrome b protein. According to the present invention, the compound represented by formula (I) [in the formula,...
|
|
WO/2021/141969A1 |
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...
|
|
WO/2021/141356A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode; and ...
|
|
WO/2021/135207A1 |
Disclosed are a nitrogen-containing compound as represented by chemical formula 1, an electronic component, and an electronic device, the nitrogen-containing compound being capable of improving the performance of the electronic component...
|
|
WO/2021/125834A1 |
The present invention provides: a novel compound capable of improving the light-emitting efficiency, stability and lifespan of an element; an organic electrical element using same; and an electronic device thereof.
|
|
WO/2021/120838A1 |
Disclosed is an organic compound, an electronic device containing the organic compound, and an electronic apparatus having the electronic device. A main structure of the organic compound is a fused heterocyclic aromatic group containing ...
|
|
WO/2021/113959A1 |
The present application discloses a compound of formula (I): compositions comprising said compound, and a method of using said compound as a cannabinoid receptor ligand in the treatment or prevention of diseases associated with a cannabi...
|
|
WO/2021/113618A1 |
Tagging agents, including fluorescent monomers, which may be polymerized. Anti-scalant polymer compositions that include a copolymer of a tagging agent and an anti-scalant monomer. Methods for synthesizing tagging agents, anti-scalant po...
|
|
WO/2021/083209A1 |
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...
|
|
WO/2021/068950A1 |
Disclosed in the present invention are an amide compound and the medical use thereof as a STING inhibitor. Specifically, disclosed is a compound represented by formula I or formula II, or a pharmaceutically acceptable salt or ester or so...
|
|
WO/2021/055849A1 |
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/018834A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, m, n and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use fo...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/000054A1 |
The present disclosure relates to a carmabinoid derivative, a pharmaceutical composition comprising it, as well as its use in the treatment and prevention of diseases associated with a carmabinoid receptor in a subject in need thereof, s...
|
|
WO/2020/253243A1 |
The present invention provides a process method for catalyzed synthesis of lactide with an alkali metal compound, comprising: mixing an alkali metal compound with a lactic acid oligomer, and carrying out a cracking reaction to obtain lac...
|
|
WO/2020/253244A1 |
The present invention provides a process for the catalytic synthesis of lactide, comprising: mixing a lactic acid oligomer with a composite catalyst; and synthesizing lactide under a heating condition, and collecting the product using a ...
|
|
WO/2020/255741A1 |
The present invention addresses the problem of providing: a hydrophilic metal-surface treatment agent which can impart water repellency to metal surfaces to inhibit the metals from corroding or discoloring; a method for treating a metal ...
|
|
WO/2020/251745A1 |
Polylactide resin compositions that exhibit rapid hydrolysis rates and leave small amounts of residuals include a poly(meso-lactide) and a second polylactide. The polylactide resin compositions are useful in applications in which rapid h...
|
